Bio-Techne Announces Licensing of Proprietary Antibody to Xencor for Therapeutic Development
This is Bio-Techne\'s third licensing agreement with Xencor, a leader in protein engineering in the immuno-oncology field.
- This is Bio-Techne\'s third licensing agreement with Xencor, a leader in protein engineering in the immuno-oncology field.
- Under the terms of this agreement, Bio-Techne grants Xencor access to a proprietary Bio-Techne antibody for use with their proprietary XmAb protein engineering technology, which is revolutionizing the development of new cancer therapeutics such as bispecific antibodies and engineered cytokines.\n"We are extremely excited about this agreement with Xencor.
- Our goal for antibody development is to create highly specific antibodies against important therapeutic targets.
- "We are proud of our long history of being the partner of choice for therapeutic antibody discovery and our innovative antibody discovery platform that is harnessed by our pharma customers to fast-track their therapeutic programs.